Soneas

Budapest, Hungary Founded: 1996 • Age: 30 yrs Acquired By Uquifa
CDMO with expertise in olefine metathesis reactions
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products 4 Services tracked
Competitors 9 Brand Intelligence

About Soneas

Soneas is a company based in Budapest (Hungary) founded in 1996 was acquired by Uquifa in May 2018. Soneas offers products and services including Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing. Soneas operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.

  • Headquarter Budapest, Hungary
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Soneas Chemicals Ltd
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Uquifa

    (May 16, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Soneas

Soneas offers a comprehensive portfolio of products and services, including Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing.

Primary

Early phase development for chemical projects and trials.

Supports chemistry understanding and innovation processes.

cGMP production of APIs and intermediates for trials.

ISO-certified large-scale chemical manufacturing operations.

Funding Insights of Soneas

Investors in Soneas

Soneas has secured backing from 1 investor. Prominent investors backing the company include UQUIFA Group.

All
Investor Description Founded Year Domain Location
CDMO company manufacturing APIs and intermediates
Founded Year Domain Location

Investments & Acquisitions by Soneas

Investments

Financial Statements - Soneas

Soneas Comparisons

+
Add Comparison
Available on Premium

Competitors of Soneas

Soneas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical and biotechnology company
domain founded_year HQ Location
Contract development, manufacturing, and analytical services for APIs are offered.
domain founded_year HQ Location
APIs and drug products are developed and valorized in pharmaceuticals.
domain founded_year HQ Location
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
domain founded_year HQ Location
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
domain founded_year HQ Location
APIs are manufactured and custom synthesis services are provided.

Latest news on Soneas

Frequently Asked Questions about Soneas

Soneas was founded in 1996.

Soneas is headquartered in Budapest, Hungary.

Soneas (formerly known as Ubichem Pharma Group) is a CDMO offering its services for API and intermediate development. The company uses catalytic olefine metathesis, in addition to other traditional manufacturing methods. The companys service portfolio includes process development (including Route selection and safety evaluation, Availability and cost of key raw materials, Process optimisation and scale-up, and Isolation and purification), cGMP API manufacture (Preclinical to commercial supply through kilo labs and pilot plants), Intermediate custom synthesis and manufacture, and analytical support services (Analytical MD MV,Impurities reference standards, Salt screening crystallisation studies, Stability studies). Soneas has a strategic partnership with XiMO AG, a Swiss-based company focused on the development and application of proprietary metathesis catalysts and founded by Richard R. Schrock, the co-winner of 2005 Nobel prize. Metathesis catalysts made up of Molybdenum and Tungsten are cheaper than those made up of Ruthenium and also help in reducing the catalytic load.

Soneas's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.

Soneas offers Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing.

Soneas has 1 investor. Key investors include UQUIFA Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available